Oncolytics BiotechONCY
About: Oncolytics Biotech Inc is a clinical-stage biopharmaceutical company. The company is focused on the discovery and development of pharmaceutical products for the treatment of cancers that have not been treated with therapeutics. It is developing pelareorep, an immunotherapeutic agent that improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The other projects in the company's pipeline include Bracelet-1 for the treatment of Breast Cancer, Goblet cohort-1, and Goblet cohort-5 for the treatment of Gastro-Intestinal Cancer among others.
Employees: 28
Fund manager confidence
Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)
100% more repeat investments, than reductions
Existing positions increased: 14 | Existing positions reduced: 7
67% more first-time investments, than exits
New positions opened: 10 | Existing positions closed: 6
10% more capital invested
Capital invested by funds: $1.1M [Q3] → $1.21M (+$107K) [Q4]
10% more funds holding
Funds holding: 42 [Q3] → 46 (+4) [Q4]
0.15% more ownership
Funds ownership: 1.55% [Q3] → 1.71% (+0.15%) [Q4]
Research analyst outlook
3 Wall Street Analysts provided 1 year price targets over the past 3 months
3 analyst ratings
Maxim Group Jason McCarthy 16% 1-year accuracy 5 / 32 met price target | 426%upside $3 | Buy Maintained | 10 Mar 2025 |
HC Wainwright & Co. Patrick Trucchio 23% 1-year accuracy 43 / 187 met price target | 777%upside $5 | Buy Reiterated | 10 Mar 2025 |
RBC Capital Douglas Miehm 50% 1-year accuracy 12 / 24 met price target | 777%upside $5 | Outperform Maintained | 10 Mar 2025 |
Financial journalist opinion
Based on 3 articles about ONCY published over the past 30 days









